Beyond Meat, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that a federal court entered a judgment of $15,437,500 against the company on September 18, 2026, following post-trial rulings in a trademark infringement case brought by Sonate Corporation.
ProPetro Holding Corp. filed a Form 8-K with the SEC on September 22, 2026, disclosing that its wholly owned subsidiary has entered into contracts to commit approximately 230 megawatts of power generation capacity to a subsidiary of Targa Resources Corp.
TriSalus Life Sciences, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that it received U.S. Food and Drug Administration 510(k) clearance for its TriNav Advance device and expects to commence commercialization.
Palmer Square Capital BDC Inc. filed an 8-K on September 22, 2026, announcing a third quarter 2026 supplemental dividend of $0.02 per share payable to shareholders of record as of September 25, 2026.
Quoin Pharmaceuticals Ltd. filed a Form 8-K with the SEC on September 22, 2026, disclosing that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational product candidate QRX003 for the treatment of Peeling Skin Syndrome.
Reborn Coffee, Inc. filed a current report on September 22, 2026, disclosing that it received a Nasdaq notice on September 16, 2026, citing non-compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.
Associated Banc-Corp filed a Form 8-K with the SEC on September 21, 2026, disclosing the planned retirement of Executive Vice President, General Counsel and Corporate Secretary Randall J. Erickson and the terms of his employment transition agreement.
CoreWeave, Inc. filed a Form 8-K on September 22, 2026, disclosing the completion of a $4.2 billion private offering of 2.875% Convertible Senior Notes due 2033, including $500 million from the full exercise of the initial purchasers' overallotment option.
Aldel Financial II Inc. filed a Form 8-K on September 22, 2026, disclosing that its sponsor and other Class B shareholders will convert substantially all of their Class B ordinary shares into Class A ordinary shares effective October 5, 2026.
LeonaBio, Inc. filed a current report on Form 8-K on September 22, 2026, disclosing that warrants issued in a December 2025 private placement became exercisable on September 18, 2026, and will remain exercisable until October 19, 2026.